中文

莱美药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-23
ItemAmountY/Y
Revenue¥0.18B-8.2%
Gross profit¥0.10B
Operating income¥-0.02B
Net income¥-0.01B
Gross margin55.0%Net margin -7.5%
Revenue Q/Q-6.4%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.08B45.0%
R&D¥0.01B5.2%
SG&A¥0.10B52.4%
Tax & other¥-0.00B-1.9%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

汉威科技天海防务安科生物ST豆神鼎汉技术华测检测新宁物流北陆药业网宿科技中元股份硅宝科技ST银江

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies